Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 36, Issue 4, Pages 918-926Publisher
WILEY
DOI: 10.1111/jgh.15241
Keywords
Corona virus; COVID-19; Crohn's disease; Immunosuppressant; Inflammatory bowel diseases; SARS-CoV-2; Ulcerative colitis
Categories
Ask authors/readers for more resources
The COVID-19 pandemic has raised concerns about the management of high-risk patients, including those with compromised immune systems, especially individuals with inflammatory bowel disease. Limited data and suggestions from medical societies aim to minimize the risk of infection in these patients during the ongoing pandemic.
The coronavirus disease 2019 pandemic has engulfed the world and is the highlight of medical community at this time. As humanity fights the battle against this virus, questions are arising regarding the appropriate management of at risk patient populations. The immunocompromised cohort is particularly susceptible to this infection, and we have tried to explore the medical management of one such group, which is composed of individuals with inflammatory bowel disease (IBD). There is limited data on the management of IBD during the ongoing pandemic. Several medical societies have put forth suggestions on how to manage immunocompromised patients in order to minimize risk of developing coronavirus disease 2019. This review aims to present available recommendations from experts and provides an insight on preventive and therapeutic strategies that can be implemented for the medical management of patients with IBD. We anticipate that as more information arises, new guidelines will emerge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available